Alterity Therapeutics Announces Positive Results from Phase 2 Trial of ATH434 for Multiple System Atrophy

Reuters

2025/07/28

<a href="https://laohu8.com/S/ATH.AU">Alterity Therapeutics</a> Announces Positive Results from Phase 2 Trial of ATH434 for Multiple System Atrophy

Alterity Therapeutics Ltd. has announced positive topline data from its open-label Phase 2 clinical trial of ATH434 in individuals with multiple system atrophy $(MSA)$. The ATH434-202 trial assessed a patient population with more advanced MSA compared to the cohort in the earlier double-blind Phase 2 trial, ATH434-201. The results demonstrated clinical benefits on the Unified MSA Rating Scale and global measures of neurological symptoms, with neuroimaging biomarkers indicating target engagement and slowed brain atrophy. ATH434 was well-tolerated and exhibited a favorable safety profile. These findings align with previous data from the Phase 2 double-blind trial and support the further advancement of ATH434 in the treatment of MSA. As of now, there are no disease-modifying medications available for MSA, making the development of ATH434 significant. The results have been presented and are consistent with Alterity's ongoing efforts to address neurodegenerative diseases.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alterity Therapeutics Ltd. published the original content used to generate this news brief on July 28, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2554749516"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2554749516\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2554749516?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-28 08:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2554749516","market":"fut","top_or_hot":-1,"title":"Alterity Therapeutics Announces Positive Results from Phase 2 Trial of ATH434 for Multiple System Atrophy","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ATH.AU\">Alterity Therapeutics</a> Announces Positive Results from Phase 2 Trial of ATH434 for Multiple System Atrophy\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Alterity <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Ltd. has announced positive topline data from its open-label Phase 2 clinical trial of ATH434 in individuals with multiple system atrophy <a href=\"https://laohu8.com/S/MSA\">$(MSA)$</a>. The ATH434-202 trial assessed a patient population with more advanced MSA compared to the cohort in the earlier double-blind Phase 2 trial, ATH434-201. The results demonstrated clinical benefits on the Unified MSA Rating Scale and global measures of neurological symptoms, with neuroimaging biomarkers indicating target engagement and slowed brain atrophy. ATH434 was well-tolerated and exhibited a favorable safety profile. These findings align with previous data from the Phase 2 double-blind trial and support the further advancement of ATH434 in the treatment of MSA. As of now, there are no disease-modifying medications available for MSA, making the development of ATH434 significant. The results have been presented and are consistent with Alterity's ongoing efforts to address neurodegenerative diseases.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alterity Therapeutics Ltd. published the original content used to generate this news brief on July 28, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Alterity Therapeutics Announces Positive Results from Phase 2 Trial of ATH434 for Multiple System Atrophy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlterity Therapeutics Announces Positive Results from Phase 2 Trial of ATH434 for Multiple System Atrophy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-28 08:17</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ATH.AU\">Alterity Therapeutics</a> Announces Positive Results from Phase 2 Trial of ATH434 for Multiple System Atrophy\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Alterity <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Ltd. has announced positive topline data from its open-label Phase 2 clinical trial of ATH434 in individuals with multiple system atrophy <a href=\"https://laohu8.com/S/MSA\">$(MSA)$</a>. The ATH434-202 trial assessed a patient population with more advanced MSA compared to the cohort in the earlier double-blind Phase 2 trial, ATH434-201. The results demonstrated clinical benefits on the Unified MSA Rating Scale and global measures of neurological symptoms, with neuroimaging biomarkers indicating target engagement and slowed brain atrophy. ATH434 was well-tolerated and exhibited a favorable safety profile. These findings align with previous data from the Phase 2 double-blind trial and support the further advancement of ATH434 in the treatment of MSA. As of now, there are no disease-modifying medications available for MSA, making the development of ATH434 significant. The results have been presented and are consistent with Alterity's ongoing efforts to address neurodegenerative diseases.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alterity Therapeutics Ltd. published the original content used to generate this news brief on July 28, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ATH.AU","symbol_name":"ALTERITY THERAPEUTICS LTD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250728:nNDL64s93X:1","article_id":"2554749516","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2554749516","pubTimestamp":1753661864,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Alterity Therapeutics Ltd. has announced positive topline data from its open-label Phase 2 clinical trial of ATH434 in individuals with multiple system atrophy . The ATH434-202 trial assessed a patient population with more advanced MSA compared to the cohort in the earlier double-blind Phase 2 trial, ATH434-201. The results demonstrated clinical benefits on the Unified MSA Rating Scale and global measures of neurological symptoms, with neuroimaging biomarkers indicating target engagement and slowed brain atrophy. ATH434 was well-tolerated and exhibited a favorable safety profile. These findings align with previous data from the Phase 2 double-blind trial and support the further advancement of ATH434 in the treatment of MSA. As of now, there are no disease-modifying medications available for MSA, making the development of ATH434 significant. The results have been presented and are consistent with Alterity's ongoing efforts to address neurodegenerative diseases.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ATH.AU":"ALTERITY THERAPEUTICS LTD","BK7067":"生物科技"},"translate_title":"Alterity Therapeutics宣布ATH434治疗多系统萎缩的2期试验取得积极结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ATH.AU":0.9},"content_text":"Alterity Therapeutics Announces Positive Results from Phase 2 Trial of ATH434 for Multiple System Atrophy\n    \n\n        Alterity Therapeutics Ltd. has announced positive topline data from its open-label Phase 2 clinical trial of ATH434 in individuals with multiple system atrophy $(MSA)$. The ATH434-202 trial assessed a patient population with more advanced MSA compared to the cohort in the earlier double-blind Phase 2 trial, ATH434-201. The results demonstrated clinical benefits on the Unified MSA Rating Scale and global measures of neurological symptoms, with neuroimaging biomarkers indicating target engagement and slowed brain atrophy. ATH434 was well-tolerated and exhibited a favorable safety profile. These findings align with previous data from the Phase 2 double-blind trial and support the further advancement of ATH434 in the treatment of MSA. As of now, there are no disease-modifying medications available for MSA, making the development of ATH434 significant. The results have been presented and are consistent with Alterity's ongoing efforts to address neurodegenerative diseases.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alterity Therapeutics Ltd. published the original content used to generate this news brief on July 28, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}